Multiple Myeloma News
Maintenance Therapy with Revlimid Slows Myeloma Progression (June 3, 2010)Maintenance therapy with RevlimidÒ (lenalidomide) slowed disease progression by 54% among patients with multiple myeloma who had undergone high-dose chemotherapy and autologous stem cell transplantation. Interim results of this Phase III study will be... Continue Reading
Kepivance Reduces Toxicity of High-dose Therapy for Multiple Myeloma (March 24, 2010)Among patients undergoing high-dose therapy and autologous stem cell transplantation for multiple myeloma, a three-day short course of Kepivance® (palifermin) reduces the toxicity of treatment. These results were published in the Annals of Oncology. Multiple... Continue Reading
Complete Remission Predicts for Long Survival in Multiple Myeloma (March 22, 2010)Achieving a complete remission was the dominant prognostic factor for long survival in patients with multiple myeloma, according to a large retrospective review published in Bone Marrow Transplantation.1 Multiple myeloma is a cancer of the blood that... Continue Reading
Benefit of Velcade on Myeloma Survival Added to Prescribing Information (March 5, 2010)The U.S. Food and Drug Administration (FDA) has approved expanded prescribing information for Velcade® (bortezomib). Velcade’s label now includes results from the VISTA study, which show that Velcade improves long-term overall survival among patients... Continue Reading
Addition of Velcade® and Revlimid® to Autologous Stem Cell Transplantation Produces Promising Results in Older Patients with Multiple Myeloma (January 7, 2010)In a Phase II clinical trial, treatment of older multiple myeloma patients with Velcade® (bortezomib) induction therapy, reduced-intensity tandem autologous stem cell transplantation, and Revlimid® (lenalidomide) consolidation-maintenance therapy produced... Continue Reading
Velcade® Improves Response Rate After High-dose Melphalan for Myeloma (December 21, 2009)Among patients who have received high-dose melphalan and an autologous stem cell transplant for initial treatment of multiple myeloma, Velcade® (bortezomib) appears to improve treatment response rates. These results were presented at the 2009 meeting... Continue Reading
Revlimid® Delays Progression of Multiple Myeloma (December 18, 2009)Among multiple myeloma patients who have had an autologous stem cell transplant, additional treatment with Revlimid® (lenalidomide) delays cancer progression. These results were released by the National Cancer Institute. Multiple myeloma is a cancer... Continue Reading
Pesticides Linked to Precancerous Blood Disorder (June 24, 2009)Pesticides Linked to Precancerous Blood Disorder Individuals who apply pesticides to crops are twice as likely as the general population to develop a precancerous blood disorder called MGUS (monoclonal gammopathy of undetermined significance), which can... Continue Reading
Formaldehyde Exposure May Increase Risk of Blood and Lymphatic Cancers (June 23, 2009)Formaldehyde Exposure May Increase Risk of Blood and Lymphatic Cancers Industrial workers who are exposed to formaldehyde may be at an increased risk of dying from blood and lymphatic cancers, particularly myeloid leukemia but also Hodgkin’s lymphoma... Continue Reading
Thalomid® – Prolongs Survival in Multiple Myeloma (April 27, 2009)One year of treatment with Thalomid® (thalidomide) and prednisone after a single autologous stem cell transplant prolongs survival in patients with newly diagnosed multiple myeloma, according to the results of a study published in the Journal of Clinical... Continue Reading
Latest Multiple Myeloma News By Stage
Recurrent Multiple Myeloma
Kepivance Reduces Toxicity of High-dose Therapy for Multiple Myeloma (March 24, 2010)
Among patients undergoing high-dose therapy and autologous stem cell transplantation for multiple myeloma, a three-day short course of Kepivance® (palifermin) reduces the toxicity of treatment. These results were published in the Annals of Oncology. Multiple... Continue Reading
Velcade® plus Perifosine Shows Promise in Relapsed or Refractory Multiple Myeloma (March 8, 2009)Velcade® plus Perifosine Shows Promise in Relapsed or Refractory Multiple Myeloma Among patients with relapsed or refractory multiple myeloma previously treated with Velcade® (bortezomib), 40% responded to treatment with a combination of Velcade and... Continue Reading
Multiple Myeloma Treatment Does Not Affect the Outcome of Stem Cell Transplant (March 8, 2009)Multiple Myeloma Treatment Does Not Affect the Outcome of Stem Cell Transplant A recently published study indicates that the type of initial chemotherapy for multiple myeloma has no impact on the outcome of patients who later undergo autologous stem cell... Continue Reading
Preventive Dental Care Reduces Osteonecrosis of the Jaw Associated with Bisphosphonates (March 8, 2009)Preventive Dental Care Reduces Osteonecrosis of the Jaw Associated with Bisphosphonates Patients who undergo preventive dental care prior to receiving therapy with bisphosphonates have a significantly reduced risk of developing osteonecrosis of the jaw.... Continue Reading
More Recurrent Multiple MyelomaStage I/Smoldering Myeloma Multiple Myeloma
Benefit of Velcade on Myeloma Survival Added to Prescribing Information (March 5, 2010)
The U.S. Food and Drug Administration (FDA) has approved expanded prescribing information for Velcade® (bortezomib). Velcade’s label now includes results from the VISTA study, which show that Velcade improves long-term overall survival among patients... Continue Reading
Velcade® Improves Response Rate After High-dose Melphalan for Myeloma (December 21, 2009)Among patients who have received high-dose melphalan and an autologous stem cell transplant for initial treatment of multiple myeloma, Velcade® (bortezomib) appears to improve treatment response rates. These results were presented at the 2009 meeting... Continue Reading
Revlimid® Delays Progression of Multiple Myeloma (December 18, 2009)Among multiple myeloma patients who have had an autologous stem cell transplant, additional treatment with Revlimid® (lenalidomide) delays cancer progression. These results were released by the National Cancer Institute. Multiple myeloma is a cancer... Continue Reading
Pesticides Linked to Precancerous Blood Disorder (June 24, 2009)Pesticides Linked to Precancerous Blood Disorder Individuals who apply pesticides to crops are twice as likely as the general population to develop a precancerous blood disorder called MGUS (monoclonal gammopathy of undetermined significance), which can... Continue Reading
Formaldehyde Exposure May Increase Risk of Blood and Lymphatic Cancers (June 23, 2009)Formaldehyde Exposure May Increase Risk of Blood and Lymphatic Cancers Industrial workers who are exposed to formaldehyde may be at an increased risk of dying from blood and lymphatic cancers, particularly myeloid leukemia but also Hodgkin’s lymphoma... Continue Reading
More Stage I/Smoldering Myeloma Multiple MyelomaStages II-III Multiple Myeloma
Maintenance Therapy with Revlimid Slows Myeloma Progression (June 3, 2010)
Maintenance therapy with RevlimidÒ (lenalidomide) slowed disease progression by 54% among patients with multiple myeloma who had undergone high-dose chemotherapy and autologous stem cell transplantation. Interim results of this Phase III study will be... Continue Reading
Kepivance Reduces Toxicity of High-dose Therapy for Multiple Myeloma (March 24, 2010)Among patients undergoing high-dose therapy and autologous stem cell transplantation for multiple myeloma, a three-day short course of Kepivance® (palifermin) reduces the toxicity of treatment. These results were published in the Annals of Oncology. Multiple... Continue Reading
Benefit of Velcade on Myeloma Survival Added to Prescribing Information (March 5, 2010)The U.S. Food and Drug Administration (FDA) has approved expanded prescribing information for Velcade® (bortezomib). Velcade’s label now includes results from the VISTA study, which show that Velcade improves long-term overall survival among patients... Continue Reading
Addition of Velcade® and Revlimid® to Autologous Stem Cell Transplantation Produces Promising Results in Older Patients with Multiple Myeloma (January 7, 2010)In a Phase II clinical trial, treatment of older multiple myeloma patients with Velcade® (bortezomib) induction therapy, reduced-intensity tandem autologous stem cell transplantation, and Revlimid® (lenalidomide) consolidation-maintenance therapy produced... Continue Reading
Velcade® Improves Response Rate After High-dose Melphalan for Myeloma (December 21, 2009)Among patients who have received high-dose melphalan and an autologous stem cell transplant for initial treatment of multiple myeloma, Velcade® (bortezomib) appears to improve treatment response rates. These results were presented at the 2009 meeting... Continue Reading
More Stages II-III Multiple Myeloma